- Home
- SITC vs ABCL Comparison
SITC vs ABCL Comparison
Compare SITC & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SITC | ABCL |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.8M | 3.5B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SITC | ABCL |
|---|---|---|
| Price | $2.87 | $11.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.00 | ★ $8.40 |
| AVG Volume (30 Days) | 861.5K | ★ 8.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 123.63% | N/A |
| EPS Growth | N/A | ★ 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $123,649,000.00 | $75,128,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $2.82 | $2.75 |
| 52 Week High | $9.09 | $12.58 |
Technical Indicators
Market Signals| Indicator | SITC | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 27.93 | 61.43 |
| Support Level | N/A | $3.39 |
| Resistance Level | $3.11 | $12.58 |
| Average True Range (ATR) | 0.08 | 0.67 |
| MACD | 0.04 | -0.19 |
| Stochastic Oscillator | 17.24 | 47.67 |
Price Performance
Historical ComparisonAbout SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.